EJA Volume 25, Supplement 44, 2008, Abstracts and Programme, EUROANAESTHESIA 2008

282 Pages·2008·5.39 MB·English

EuropeanJournalofAnaesthesiology
Volume25,Supplement44,2008
Abstracts and Programme
EUROANAESTHESIA 2008
The European Anaesthesiology Congress
Copenhagen, Denmark,
31 May–3 June 2008
European Journal of Anaesthesiology
Editor-in-Chief Editors Editor of Supplements
B. J. Pollard Manchester, UK J.-P. Haberer Paris, France B. Matta Cambridge, UK
M. Tramèr Genève, Switzerland
Deputy Editor-in-Chief and Editor of G. Capogna Roma, Italy
Editor of EACTA Supplements
Commissioned Reviews H. Tydén Uppsala, Sweden R. Feneck London, UK
T. A. Crozier Göttingen, Germany M. Leuwer Liverpool, UK
A. W. Gelb London, Canada
L. Bogar Pécs, Hungary Statistical Adviser
C. J. D. Pomfrett Manchester, UK
B. Matta Cambridge, UK
C. Bailey London, UK
P. Rosenberg Helsinki, Finland Associate Editors
M. Columb Manchester, UK C. J. D. Pomfrett Manchester, UK
S. De Hert Genk, Belgium N. J. N. Harper Manchester, UK
Editorial Board
Chairman A. R. Aitkenhead Nottingham, UK
Members
A. Hoeft Bonn, Germany
B. Matta Cambridge, UK
H. Van Aken Münster, Germany
Editor-in-Chief
Deputy Editor-in-Chief
*P. Simpson Bristol, UK, President of the European Society of Anaesthesiology
*E. Kochs Munich, Germany, Secretary of the European Society of Anaesthesiology
*M. Tramèr Geneva, Switzerland, Treasurer of the European Society of Anaesthesiology
*C.-J. Jakobsen Aarhus, Denmark, President of the European Association of Cardiothoracic Anaesthesiologists
*J. T. A. Knape Utrecht, Netherlands, President of the Union Européenne des Médecins Spécialistes, Section of Anaesthesiology
*P. Scherpereel Lille, France, President of the Fondation Européenne d’Enseignement en Anesthésiologie
[*Ex-officio]
Commissioning Editor
Dan Edwards (E-mail: [email protected])
European Journal of Anaesthesiology (EJA) is the official publication of the Despatch. European Journal of Anaesthesiology is dispatched within the UK
European Society of Anaesthesiology. The EJA is also the official journal by 2nd class post, within Europe by airmail, and to other countries by var-
of the following organizations: EACTA (European Association of ious forms of air-speeded delivery. Add to the cost of regular subscription
Cardiothoracic Anaesthesiologists), EFAAD (European Federation for the £12/$18 for airmail delivery outside Europe.
Advancement of Anaesthesia in Dentistry), ESCTAIC (European Society
for Computing and Technology in Anaesthesia and Intensive Care), the Editorial material should be sent to the Editor, European Journal of
FEEA (Fondation Européenne d’Enseignement en Anesthésiologie), Anaesthesiology, Cambridge University Press, Edinburgh Building,
SESAM (Society in Europe for Simulation Applied to Medicine) and of the Shaftesbury Road, Cambridge CB2 8RU, UK. E-mail: journals_societies@
Section Anaesthesiology of the UEMS (Union Européenne des Médecins cambridge.org.
Spécialistes). The Journal publishes original scientific work. Preference is
given to experimental work or clinical observations in man, and to labo- Business correspondence, including orders for offprints and advertising,
ratory work of clinical relevance. There will be regular commissioned should be sent to the publishers: European Journal of Anaesthesiology, Adver-
reviews by an authority in a field of interest to those working in anaesthe- tising Department, Cambridge University Press, Edinburgh Building,
siology or intensive care. Shaftesbury Road, Cambridge CB2 8RU, UK. E-mail: ejaeditorial@
cambridge.org. Information on this journal is available on the website:
Subscription information. European Journal of Anaesthesiology is published www.journals.cambridge.org.
monthly (one volume per annum) and the subscription prices for 2007
are as follows. Institutional: €1014 (Europe), $1173 (USA and Canada) Copyright and photocopying: © 2007 European Society of Anaesthesiology.
and £744 (Rest of the World); Personal: €244 (Europe), $249 (USA and Authorization to photocopy items for internal or personal use, or the inter-
Canada), £160 (Rest of the World), in all cases post-free. Subscribers nal or personal use of specific clients, is granted by the European Society of
in Canada must add 7% to the subscription price, to allow for GST. Anaesthesiology for libraries and other users registered with their national
Subscribers in Europe must quote their VAT registration number or state Reproduction Rights Organisations – such as the the Copyright Clearance
that they are not registered. Subscribers in the following countries who Center (USA), Copyright Licensing Agency (UK), and the Copyright
are not VAT-registered must add VAT at the appropriate rate: Belgium Agency Limited (Australia) – provided that payments are made to the rel-
(6% TVA/BTW), France (2.1% TVA), Germany (7% MWST), Spain evant Organisation at the base rates currently prevailing. This consent does
(4% IVA), The Netherlands (6% BTW). Orders for current subscriptions not extend to other kinds of copying, such as copying for general distribu-
and back issues should be sent to EJA Subscription Orders, Cambridge tion for advertising or promotional purposes, for creating new collective
University Press, Edinburgh Building, Shaftesbury Road, Cambridge works or for resale. Special requests should be addressed to the Editor.
CB2 8RU, UK. E-mail: [email protected].
The views expressed in this journal represent those of the authors only. In
The Publishers’ Policy is to use acid-free permanent paper, to the draft stan- no way can they be construed necessarily to reflect the view of either the
dard ISO/DIS 9706, made from sustainable forests using chlorine-free pulp. Editors or the Publishers.
EUROANAESTHESIA 2008
The European Anaesthesiology Congress
Copenhagen, Denmark, 31 May–3 June 2008
ABSTRACT PRESENTATION PROGRAMME
Pleasenotethatallabstractsarepresentedasposterpresentations:abstractpresentersdonotmakeaformalpresentationoftheirabstract
inaseparateroom,usingaudiovisualaids(exceptfortheESABestAbstractPrizeCompetition(BAPC)andtheBestAbstracts–Runner-up
Session1&2).Instead,twochairpersonswillconduct,infrontofeachposter,ashortdiscussionofeachabstractwiththepresenterand
theaudience,foreveryabstractinthatsession.Posterpresentershavebeenaskedtostandbytheirposterfor45minutesbeforeand30
minutesaftertheirsession,toaddressfurtherquestions.
PosterBoardlocation
Allpostersofregularabstract sessionswillbedisplayedinHallA1.Eachabstractpresentationsessionisdisplayedinadifferentposter
boardrow.Rowsarenumbered,toeasilylocateagivensession.Thefirstboardofeachrowcontainsaninformationboardthatliststhe
sessionreference,date,timeandchairperson(s).
Note:AllabstractsessiondetailsinthisSupplementarecorrectatthetimeofprinting.Sessiondatadisplayedontheinformationboards,in
particularchairpersonnames,maybemoreuptodate.
NotethattheBestAbstractPrizeCompetition,withsessionreferenceESAPC1,takesplaceinRoomB5,asdotheBestAbstracts–Runner-
upSession1andtheBestAbstracts–Runner-upSession2.Thepostersofthese“best”abstracts,however,willalsobeondisplayinHall
A1forthedurationofthecongress.
Locatinganabstract
Theacceptedabstractnumberformatconsistsofthesessionreference,followedbyanumberdenotingtheorderoftheabstractwithinthis
session:forexample,session6AP1wouldbethefirst(1)AbstractPresentation(AP)sessionforsubcommittee6).Thefirstabstracttobe
presentedinsession6AP1willthusbecalled6AP1-1,thesecondone6AP1-2andsoon.(Theremaybeomissionsinthenumberingdue
towithdrawnabstracts.)
Tolocateabstract6AP1-2orotherabstractsforsession6AP1,lookforthesessionreference(6AP1)intheschedulelistedbelow,thenfind
theappropriatepagenumber,whichalwaysreferstothepagenumberofthefirstabstractwithinthespecifiedsession.
Thenumberoftheposterboardrowisindicatedforeachsession.Tofindtheposterboardforabstract6AP1-2,gototheposterboardrow
indicatedforsession6AP1(onthedayofpresentation),thenlookfortheposterboardwithnumbertwoindicatedatthetop.
Date Time Reference Room/RowinHallA1 Page
ESABestAbstractPrizeCompetition(BAPC)
Sunday,June1 12:15–13:45 ESAPC1 RoomB5 1
BestAbstracts–Runner-upSessions
Sunday,June1 08:30–10:00 ESAAP1 RoomB5 2
Sunday,June1 10:30–12:00 ESAAP2 RoomB5 4
Subcommittee1–Evidence-basedpracticeandqualityassurance
Sunday,June1 10:15–11:45 1AP1 ROW2B 6
Sunday,June1 16:00–17:30 1AP2 ROW1B 9
Monday,June2 10:30–12:00 1AP3 ROW1A 12
Monday,June2 16:00–17:30 1AP4 ROW2A 14
Subcommittee2–Ambulatoryanaesthesia
Sunday,June1 10:15–11:45 2AP1 ROW4B 18
Sunday,June1 14:00–15:30 2AP2 ROW2A 20
Monday,June2 16:00–17:30 2AP3 ROW4A 22
Subcommittee3–Monitoring:equipmentandcomputers
Saterday,May31 15:15–16:45 3AP1 ROW2B 24
Sunday,June1 12:15–13:45 3AP2 ROW1A 27
Sunday,June1 12:15–13:45 3AP3 ROW3A 31
Sunday,June1 16:00–17:30 3AP4 ROW3B 34
Sunday,June1 16:00–17:30 3AP5 ROW5B 38
Monday,June2 16:00–17:30 3AP6 ROW6A 40
Monday,June2 16:00–17:30 3AP7 ROW8A 44
iv Contents
Subcommittee4–Clinicalandexperimentalcirculation
Saterday,May31 15:15–16:45 4AP1 ROW4B 47
Sunday,June1 12:15–13:45 4AP2 ROW5A 51
Sunday,June1 12:15–13:45 4AP3 ROW7A 53
Sunday,June1 14:00–15:30 4AP4 ROW4A 57
Sunday,June1 14:00–15:30 4AP5 ROW6A 59
Monday,June2 16:00–17:30 4AP6 ROW10A 62
Monday,June2 16:00–17:30 4AP7 ROW11A 64
Tuesday,June3 10:30–12:00 4AP8 ROW1B 66
Subcommittee5–Respiration
Sunday,June1 10:15–11:45 5AP1 ROW6B 69
Sunday,June1 10:15–11:45 5AP2 ROW8B 72
Monday,June2 14:00–15:30 5AP3 ROW2B 74
Tuesday,June3 10:30–12:00 5AP4 ROW3B 77
Subcommittee6–Transfusionandhaemostasis
Saterday,May31 13:15–14:45 6AP1 ROW1B 80
Sunday,June1 12:15–13:45 6AP2 ROW9A 83
Sunday,June1 14:00–15:30 6AP3 ROW8A 87
Monday,June2 16:00–17:30 6AP4 ROW12A 89
Subcommittee7–Neurosciences
Sunday,June1 10:15–11:45 7AP1 ROW10B 92
Sunday,June1 16:00–17:30 7AP2 ROW7B 94
Monday,June2 10:30–12:00 7AP3 ROW3A 96
Monday,June2 10:30–12:00 7AP4 ROW5A 98
Monday,June2 14:00–15:30 7AP5 ROW4B 101
Tuesday,June3 10:30–12:00 7AP6 ROW5B 104
Subcommittee8–Localandregionalanaesthesia
Saterday,May31 15:15–16:45 8AP1 ROW6B 107
Saterday,May31 15:15–16:45 8AP2 ROW8B 109
Sunday,June1 12:15–13:45 8AP3 ROW11A 112
Sunday,June1 14:00–15:30 8AP4 ROW10A 114
Sunday,June1 14:00–15:30 8AP5 ROW12A 116
Sunday,June1 16:00–17:30 8AP6 ROW9B 118
Tuesday,June3 10:30–12:00 8AP7 ROW7B 121
Subcommittee9–Pharmacology
Sunday,June1 12:15–13:45 9AP1 ROW13A 125
Sunday,June1 12:15–13:45 9AP2 ROW15A 127
Sunday,June1 16:00–17:30 9AP3 ROW11B 130
Sunday,June1 16:00–17:30 9AP4 ROW13B 132
Monday,June2 10:30–12:00 9AP5 ROW7A 135
Monday,June2 10:30–12:00 9AP6 ROW9A 138
Monday,June2 16:00–17:30 9AP7 ROW14A 141
Monday,June2 16:00–17:30 9AP8 ROW16A 144
Tuesday,June3 10:30–12:00 9AP9 ROW13B 147
Subcommittee10–Paediatricanaesthesiaandintensivecare
Saterday,May31 13:15–14:45 10AP1 ROW3B 151
Sunday,June1 16:00–17:30 10AP2 ROW15B 154
Monday,June2 16:00–17:30 10AP3 ROW18A 157
Subcommittee11–Obstetricanaesthesia
Saterday,May31 15:15–16:45 11AP1 ROW12B 159
Monday,June2 14:00–15:30 11AP2 ROW6B 161
Subcommittee12–Intensivecaremedicine
Saterday,May31 15:15–16:45 12AP1 ROW14B 164
Sunday,June1 10:15–11:45 12AP2 ROW12B 167
Sunday,June1 12:15–13:45 12AP3 ROW17A 169
Sunday,June1 12:15–13:45 12AP4 ROW19A 172
Sunday,June1 14:00–15:30 12AP5 ROW14A 175
Monday,June2 10:30–12:00 12AP6 ROW11B 178
Monday,June2 10:30–12:00 12AP7 ROW13A 180
Monday,June2 14:00–15:30 12AP8 ROW8B 183
Contents v
Subcommittee13–Resuscitationandemergencymedicine
Saterday,May31 13:15–14:45 13AP1 ROW5B 186
Monday,June2 14:00–15:30 13AP2 ROW12B 189
Tuesday,June3 10:30–12:00 13AP3 ROW15B 190
Subcommittee14–Acuteandchronicpainmanagement
Saterday,May31 13:15–14:45 14AP1 ROW7B 193
Saterday,May31 13:15–14:45 14AP2 ROW9B 195
Saterday,May31 15:15–16:45 14AP3 ROW16B 198
Sunday,June1 10:15–11:45 14AP4 ROW14B 202
Sunday,June1 10:15–11:45 14AP5 ROW16B 204
Sunday,June1 12:15–13:45 14AP6 ROW20B 207
Sunday,June1 14:00–15:30 14AP7 ROW16A 210
Sunday,June1 16:00–17:30 14AP8 ROW17B 213
Monday,June2 10:30–12:00 14AP9 ROW15A 215
Monday,June2 10:30–12:00 14AP10 ROW17A 216
Monday,June2 14:00–15:30 14AP11 ROW14B 219
Monday,June2 14:00–15:30 14AP12 ROW16B 221
Subcommittee15–Education,researchandpresentation
Sunday,June1 14:00–15:30 15AP1 ROW18A 223
Monday,June2 10:30–12:00 15AP2 ROW19A 226
Subcommittee17–Patientsafety
Sunday,June1 10:15–11:45 17AP1 ROW18B 228
Monday,June2 10:30–12:00 17AP2 ROW21A 231
Monday,June2 14:00–15:30 17AP3 ROW18B 233
Subcommittee19–Airwaymanagement
Saterday,May31 15:15–16:45 19AP1 ROW18B 236
Saterday,May31 15:15–16:45 19AP2 ROW20B 238
Sunday,June1 12:15–13:45 19AP3 ROW22B 241
Sunday,June1 16:00–17:30 19AP4 ROW19B 243
Sunday,June1 16:00–17:30 19AP5 ROW21B 246
Monday,June2 16:00–17:30 19AP6 ROW20A 249
Monday,June2 16:00–17:30 19AP7 ROW22B 253
Tuesday,June3 10:30–12:00 19AP8 ROW17B 255
The abstracts published in this Supplement have been typeset from electronic submissions and camera-ready copies prepared by the
authors.Everyefforthasbeenmadetoreproducefaithfullytheabstractsassubmitted.Theseabstractshavebeenpreparedinaccordance
with the requirements of the European Society of Anaesthesiology and have not been subjected to review nor editing by theEuropean
JournalofAnaesthesiology.However,noresponsibilityisassumedbytheorganizersorpublisherforanyinjuryand/ordamagetopersons
or property as a matter of products liability, negligence or otherwise, or from any use or operation of methods, products, instructions or
ideascontainedinthematerialherein.Becauseoftherapidadvancesinmedicalsciences,werecommendthatindependentverificationof
diagnosesanddrugdosesshouldbemade.
Call for abstracts
The ESA solicits the submission of abstracts for the
Euroanaesthesia 2009 Meeting
Milan, Italy
6-9 June 2009

All abstracts must be submitted online via the ESA Website
www.euroanesthesia.org

The submission module will be available to submitters
from November 1st to December 15th 2008

Submission Conditions

When submitting your abstract, you will be prompted to accept the
submission conditions that will be made available on the ESA website at
least one month before the submission starts.
ESA Best AbstractPrize Competition(BAPC)
ESAPC1-1 cellsdisplayedgradualdevelopmentofmechanicalallodyniaandthermalhyper-
XenonreducesNMDA-receptormediatedsynaptic algesia,beginningfromday7followinginjectionofcells.TwosiRNAswereiden-
transmissioninthemouseamygdalaviapostsynaptic tifiedthatwerecapableofahighly-selectiveattenuationofNav1.8messagein
mechanismsandindependentontheNR2AorNR2Bsubunit culturedDRGcells.IntrathecalinjectionofM-siRNA,butnotthenegativecontrol
RNAorvehiclealone,attenuatedmechanicalallodyniaandthemalhyperalgisa
R.Haseneder,S.Kratzer,E.Kochs,W.Zieglgänsberger,G.Rammes
ofbonecancerpain.IntrathecaladministrationofM-siRNAwasconcomitant
DepartmentofAnesthesiology,KlinikumRechtsderIsar,Technische withareductionintheNav1.8transcriptsinthelumbarDRG.Negativecon-
UniversitätMünchen,Munich,Germany trolRNAinjectiondidnotalterexpressionofNav1.8inlumbarDRG,andhad
BackgroundandGoalofStudy:Althoughtheneuronalmechanismsofthe noeffectonthebaselinethresholdofnociception.Theantinociceptioneffectof
anaestheticgasXenon(Xe)arenotyetfullyunderstood,thereisevidencefrom M-siRNAcontinuedto72hafterthelastRNAinjection.
studiesusingneuronsinculture(1),thattheNMDAreceptorisamajortarget Conclusion(s):WeconcludethatsilencingofNav1.8channelusingasiRNA
forXeaction.Inthepresentstudy,weinvestigatedthemechanisms,howXe approachiscapableofproducingallodyniaandhyperalgesiareliefinthebone
reducesNMDAreceptormediatedsynaptictransmissioninaninvitrobrainslice cancemodel.
preparationofthemouseamygdala.
Materials and Methods: Coronar brain slices were obtained from male
mice(Bl6;d28-35). Neurons inthebasolateral amygdala wereidentified by ESAPC1-3
infrared-phasevideomicroscopy. Fromtheseneurons,pharmacologically iso- InfluenceofrhDNAseonthedurationofmechanical
lated NMDA receptor mediated currents were recorded using patch clamp ventilationinintensivecarepatients
technique.Thecurrentswereevokedeitheruponelectricalstimulation(NMDA-
N.Deschner,W.Brehm,R.Vonthein,J.Riethmueller
eEPSCs)oruponfocal,laser-guidedphotolysisofcagedL-glutamate(p-NMDA-
Cs).Undercontrol conditions,thesliceswerekeptinartificialcerebro-spinal Dept.ofAnaesthesiologyandIntensiveCareMedicine,UniversityHospital
fluid (ACSF)gassed with 65% N2/30% O2/5% CO2. For Xe application, the Tuebingen,Tuebingen,Germany
ACSFwasgassedwith65%Xenon/30% O2/5% CO2.NVP-AAM077(NVP), Background and Goal ofStudy: RhDNaseis effective inthetreatment of
andRo25-6981 (Ro),whichareselectiveantagonists oftheNMDAreceptor childrenwithcysticfibrosis[1].Significantreductionofdurationofventilationby
NR2A(2)andNR2B(3)subunit,respectively,wherebathappliedatknowncon- rhDNAsehasbeenreportedinchildrenfollowingcardiacsurgery[2].Thegoal
centrationsviathesuperfusionsystem. ofthisstudywastoinvestigatewhetherrhDNaseisabletoreducetheduration
Results and Discussion: Xe reversibly reduced electrically evoked NMDA- ofventilationinadultmechanicallyventilatedintensivecarepatients.
eEPSCsto64.6±5.3%ofcontrol(n=6).Whenmimickingsynapticresponses MaterialsandMethods:Afterapprovaloflocalethicscommitteeswecon-
byuncagingglutamate,p-NMDA-CswerereducedinthepresenceofXetoa ducted adouble-blind,placebo-controlled, randomised, multi-centrenational
similarextent(72.9±5.1%,n=6;p>0.05vs.NMDA-eEPSCs).Totestwhether trial.Patientswerestratifiedintwosubgroupsdependingontheirstatusassur-
Xe-induceddepressionoftheNMDAreceptor-mediatedsynaptictransmission gicalornon-surgical.Thetrialwasstartedwithin48hafterstartofmechanical
isdependentonthefunctionalityoftheNR2AorNR2Bsubunit,p-NMDA-Cs ventilationandlasteduntilweaningwassuccessful.Patientsinthetreatment
wererecordedinthepresenceoftheselectiveantagonistsNVP(50nM)orRo groupreceived2,5mlofrhDNaseendotracheally twiceaday.Patientsinthe
(0.5μM).TheXeinducedreductionundertheseconditionswasnotsignificantly placebogroupreceivedthesameamountofnormalsaline.
differentfromthatwithoutNR2AorNR2Bblockade,respectively,indicatingthat ResultsandDiscussion:123surgicaland162non-surgicalpatientswerein-
Xeexertsitseffectatneitherofthesesubunits. cludedinthestudy.Factorslikegender,weight,smokinghabit,chronicpre-
Conclusion(s): In the present study we found a pronounced depression of existing diseases and prevalence of COPD were distributed equally in both
NMDAreceptormediatedsynaptictransmissioninthemousebasolateralamyg- groups insurgicalpatients.Innon-surgicalpatientsmoresmokerswereran-
dala.TheeffectsofXecantherebybeexplainedbyapostsynapticmechanism. domizedtotherhDNasegroup.Acuteburnpatientswererandomizedtothe
Additionally,weprovideevidence,thatthepharmacologicaltargetofXemight rhDNasegrouponly.12patients(2surgical)diedintherhDNasegroupver-
bepredominantlytheNR1subunit. sus16(4surgical)intheplacebogroup.Insurvivingsurgicalpatientsmedian
References: durationofventilationwas16.6days(CI11.5to21days)intherhDNaseand
1 DeSousaS,DickinsonR,LiebWR,etal.Anesthesiology2000;92:1055–66. 11.7days(CI8.4to15.6days,p=0.39)intheplacebogroup.Insurvivingnon-
2 AubersonYP,AllgeierH,BischoffS,etal.BioorgMedChemLett2002;12:1099–1102. surgicalpatientsmediandurationofventilationwas7.8days(CI6to9.3days)in
3 FischerG,MutelV,TrubeG,etal.JPharmacolExpTher.1997;283:1285–92. therhDNaseand12.6days(CI7.9to16.9days;p=0.038)intheplacebogroup
withoutadjustmentforsmokinghabits.Inadultnon-surgicalintensivecarepa-
tients,rhDNasesignificantlyshortensthedurationofventilation.Thiseffectis
ESAPC1-2 notseeninsurgicalpatients.Thehypothesisthatespeciallypneumoniathatre-
AlleviateallodyniaandhyperalgesiabysilencingofNav1.8 quiresmechanicalventilationresponds favourablytotreatmentwithrhDNase
withsiRNAinbonecancerpainrats shouldbeinvestigated.
Conclusion(s):RhDNaseisabletoreducethedurationofventilationinadult
L.Xu,Y.Liu,H.Zhang
non-surgicalintensivecarepatients.
Anesthesiology,PLAGeneralHospital,Beijing,China Disclosure: Travel expenses are paid by Roche, the manufacturer of Pul-
BackgroundandGoalofStudy:Thegoalofthestudywastoevaluatethe mozyme.
invivogenesilencingeffectofNav1.8indorsalrootanglia(DRG)byintrathecal References:
administrationofchemicallysynthesizedsiRNAwith3’terminalmethylmodifi- 1 Fuchsetal.,NEnglJMed1994;331:637–642.
cation,andtoinvestigatetheantinociceptiveeffectofsiRNAtargetingNav1.8 2 RiethmuellerJetal.,PediatrPulmonol.2006;41:61–6.
inaratmodelofbonecancerpain.
MaterialsandMethods:(1)FemaleSDratsrecievedintra-tibialinjectionof
5×104syngeneticWalker256mammaryglandcarcinomacells.Mechanicalal- ESAPC1-4
lodyniaandthermalhyperalgesiaweretestedaftercellinjection.(2)Threepairs Annon-O2consuminginotropedrugimprovessurvivalinan
ofsiRNAtargetingNav1.8byinvitrotranscriptionwithT7RNApolymerasewere animalmodelofcardiacarrest
synthesized.Amismatchedduble-strandRNAwaschoosedasnegativecontrol
E.Koudouna,T.Xanthos,E.Dassiakou,D.Perrea,L.Papadimitriou
RNA.siRNAweretransfectedintoprimaryculturedDRGneuronsandmRNA
expressionofNav1.8wasdeterminedwithRT-PCRandQ-PCR48hafterthe ExperimentalSurgeryandSurgicalResearch,UniversityofAthens,Athens,
transfecion.(3)WesynthesizedsiRNAchemicallyaccordingtothesequence Greece
thatcanmosteffectivelyattenuationofNav1.8mRNAinvitroand3’terminalof BackgroundandGoalofStudy:Cardiacarrestremainstheleadingcause
siRNAwasmethylmodified(M-siRNA).M-siRNA,negativecontrolRNAandnor- of death in Europe. The role of adrenaline remains controversial, due to its
malsalineweredeliveredasrepeateddailybolusdoses(25-100ug,for7days) beta-adrenergiceffects,whichareknowntoinducepost-resuscitationmyocar-
viaimplantedintrathecalcathetertothelumbarspinalcordofbonecancerrats. dialdysfunction.Thegoalofthisstudy wastodeterminewhetheranon-O2
Mechanicalallodyniaandthermalhyperalgesiaweretestedeverydayafterin- consuminginotropedrug,suchaslevosimendan,incombinationtoadrenaline,
trathecalinjection.(4)L4-6DRGoftheratswasobtainedtwenty-fourhoursafter duringresuscitation,wouldimprovesurvival.
thelastsiRNAinjection.Nav1.8expressionintheDRGwasevaluatedbyusing Materials and Methods: Thirty two healthy Landrance/Large White piglets
ofRT-PCRandQ-PCRmethods. 20±1.7kg aged 16-18 weeks, were randomized into 2 groups (16 animals
Results and Discussion: Ratsreceivingintra-tibial injections ofwalker256 each).Coronaryperfusionpressurewasmonitoredduringtheresuscitationpe-
2 BestAbstracts–Runner-upSession1
riod.Usingapacingwirethroughtheinternaljugularvein,ventricularfibrillation ducedspontaneousacutepain(NRS=6of10)andstableareasofpinprick-
wasinducedtoallanimalsandleftuntreatedfor6minutes.AnimalsinGroup hyperalgesiaandallodynia.Painintensitiesaswellastheareasofhyperalgesia
A receivedsalineas placebo (10ml dilution, bolus)+adrenaline (0.02mg/kg) wereassessedbeforeandaftera10dayslastingintakeofeitherrimonabantat
andanimalsinGroupBreceivedlevosimendan(12mcg/kg/10ml dilution,bo- anoraldoseof20mgonceperday(sufficienttoreach>90%ofthesteady
lus)+adrenaline(0.02mg/kg)duringcardiorespiratoryresuscitation(precordial stateplasmalevel)orplacebo.Eachsessionwasperformedoveraperiodof
compressionsandmechanicalventilation).Electricalfibrillationwasattempted 100minwhileacuteongoingpainaswellasareasofallodyniaandhyperalgesia
after8minutesofcardiacarrest(6minofuntreatedventricularfibrillationand wereassessedatregularintervals.Stimulationintensityinsession1andsession
2minofcardiorespiratoryresuscitation).Coronaryperfusionpressure(CPP)was 2wasidentical.Statisticalanalysiswasperformedontheintegralofpainratings
monitoredduringresuscitationperiod.Animalswithreturnofspontaneouscir- andhyperalgesicandallodynicareasizes(cm2)overtime(min).
culation(ROSC)wereplacedbacktotheircagesfor48hours,inordertorecord ResultsandDiscussion:Rimonabanttreatmenthadnoeffectontheratings
survival. ofacutepaininducedbyelectricalstimulation(NRSdecrease:-2.0±5.7%,n=
Results and Discussion: Sevenanimals inGroup Arestored spontaneous 8volunteerseach,P=0.75,pairedStudentt-test).However,thesizesofhyper-
circulationand4survivedfor48hoursafterROSC,incomparisonto16ani- algesicandallodynicskinareasweresignificantlydecreasedintherimonabant-
malswhichrestoredspontaneouscirculation(p<0.05)and14,whichsurvived treatedgroup(hyperalgesia:46.3±5.2%,P<0.001;allodynia:42.6±5.0%,P
(p<0.05)inGroupB.CPPwassignificantlyhigher(p<0.05)duringresuscita- =0.0074).
tioninGroupB.Inconclusion,anon-O2consuminginotrope,whenadminis- Conclusion(s):Ourresultsprovidefirstdataaboutreductionofcentralsensi-
teredduringcardiorespiratoryresuscitation,significantlyimprovessurvivaland tisationinahumanpainmodelcausedbyaCB1receptorantagonist.These
increasescoronaryperfusionpressureduringresuscitation.Levosimendanisan findingsattributetoendocannabinoidsanovelpronociceptivefunctionindor-
inotropedrug,whichisknownnottoincreaseoxygenconsumptionbythemy- sal horn neuronal circuits whichmay limitthe analgesicefficacy ofsystemic
ocardiumorinducearrythmias.Inaddition,levosimendanisknowntodecrease cannabinoidagonists.
rightatriumsystolicanddiastolicpressures.Itwasthereforelogicalthatlevosi- References:
mendanwouldincreaseCPP,whichistheonlypredictingfactorofROSC,and 1 V.Chevaleyre,K.A.Takahashi,P.E.Castillo,AnnuRevNeurosci(Mar15,2006).
improvesurvival,astheanimalswouldnotbeexpectedtohavelife-threatening
post-resuscitationmyocardialdysfunction.
ESAPC1-6
Conclusion(s):Levosimendan,co-administeredwithadrenalinebeforedefib-
rillation,improvessurvivalinthisanimalmodelofcardiacarrestandcardiopul- Sevofluraneinducedpreconditioningintheisolatedmouse
monaryresuscitation. heart:Aroleforcaveolin-1
M.Damm,A.Heintz,P.Panousis,T.Koch,S.Stehr
ESAPC1-5 DepartmentofAnaesthesiologyandIntensiveCareMedicine,MedicalFaculty
CarlGustavCarus,UniversityHospitalDresden,Dresden,Saxony,Germany
TheCB1-receptorantagonistrimonabantreducescentral
BackgroundandGoalofStudy:Caveolae,smallinvaginationsintheplasma
sensitisationinahumanpainmodel
membraneandtheirmainscaffoldingproteinCaveolin-1areessentialproteins
J.Filitz,A.Nieberle,H.Zeilhofer,W.Koppert forsignaltransductionandtransportationprocessinsidethecell.Thereisevi-
DepartmentofAnaesthesiology,UniversityHospital,Erlangen,Germany dencethatcaveolaehaveapotentialroleincardiacprotectionthroughischemia
BackgroundandGoalofStudy:ReducedglycinergicandGABAergicinhi- andreperfusion.Wetestedthehypothesisthatcaveolaearealsoinvolvedin
bitionisthoughttounderliesecondaryhyperalgesiaelicitedbyintensepainful sevofluraneinducedpreconditioningintheisolatedmouseheart.
stimulation.Spinalendocannabinoids producedinresponsetopainfulstimu- MaterialsandMethods:Twelve6-wk-oldmaleC57BL/6(WT)andCaveolin-1
lationaresuspectedtoservethisfunction.Aimofthisstudywastoexamine knockoutmice(CAV-1-KO)wereanaesthetisedwithpentobarbitalsodium(70
theanalgesicandantihyperalgesicproperties oftheCB1-receptorantagonist mg/kg/h).Heartswererapidlyremovedduringcontinuouscoolingandmounted
rimonabantinanexperimentalpainmodelinhumans. viaaortaonaperfusioncannula.Heartswereallowedtoequilibratefor20min
andweresubjectedtocarbogeninthecontrolgroup(WTcontrol,n=6;CAV-1-
KOcontrol,n=6)or2.8%sevofluraneinthesevofluranegroup(WTsevo,n=6;
CAV-1-KOsevo,n=6)for15min.Aftera10minperiodofwashoutallhearts
underwent60minischemiathroughligationoftheleftcoronaryartery(LCA).
A 30 minreperfusion period followed. Ventricular pressure (LVP),dP/dtmax,
heartrate,coronary flowandcoronary perfusionpressurewerecontinuously
measured.Arterialandvenousperfusatesampleswerecollected.Thenormal
perfusedarea,theareaperfusedbytheLCA(areaatrisk,AAR)andthesize
oftheinfarctitselfweredeterminedbyusingastainingtechniquewithmicro-
spheresandpropidiumiodide.Infarctsizewascalculatedasthepercentageof
myocardialinfarctioncomparedwiththeAAR.Dataanalysiswasperformedus-
ingOne-Way-ANOVAandpost-hocanalysisbyBonferroni.
ResultsandDiscussion:Intheisolatedperfusedmouseheart60minofleft
coronaryocclusionand30minofreperfusioncausedmyocardialinfarctionof
67.3±2.3%inWT-groupandof67.0±2.8%in,respectivelyCAV-1-KOgroup.
Sevofluranereducedinfarctionby50.1%to33.6±2.1%(p≤0.01)intheWT
heartsandbyonly18.5%to54.7±3.4%intheCAV-1-KOhearts(p≤0.01).
Conclusion(s):Sevofluraneinducedpreconditioning intheisolatedperfused
Materials and Methods: After approval of the local ethics committee, 16 mouse heart as infarct sizes were significantly decreased. This effect was
healthy volunteers were enrolled in this double-blind and placebo-controlled presentinWTandCAV-1-KOmouse.Sevofluraneinducedpreconditioningis
studyandwererandomizedintotwosex-andage-matchedgroupsof8per- interestinglylimitedintheCaveolin-1knockouthearts.Therefore,caveolin-1is
sonseach.Transcutaneous electricalstimulationathighcurrentdensitiesin- likelytobeofmajorimportanceforsevofluraneinducedpreconditioning.
Best Abstracts– Runner-up Session 1
ESAAP1-1 poor,weconductedarandomizedcontrolledexperimentaimingatmeasuring
Colourcoding:Awaytopreventsyringeswaperrors(ssE) theimpactofcolourlabelsonssE,keepinginmindthatassEalwaysresults
P.Garnerin,D.Tsoncheva,P.Chopard,T.Perneger,P.Bonnabry frombothasyringeselectionerror(Esel)andeitherachecknotperformed(Ochk)
oracheckperformedbutfailed(Fchk).
AnaesthesiologyService,GenevaUniversityHospitals,Geneva,Switzerland MaterialsandMethods:Viaacomputerscreen,participantswereaskedto
BackgroundandGoalofStudy:TopreventssE,ithasbeensuggestedto pick-upasyringeofafictivedrugfromatraycontaining2,4,6or8items,
resortoncolourcodingofdrugs.Asevidenceinfavourofthisproposalwas anddecidewhethertheywouldinjectit,byinsertingthesyringeineitherthe
BestAbstracts–Runner-upSession1 3
“inject”or“inject”slotattachedtothetray.Threefactors-i.e.b&wvs.colour 3 EvronS,GladkovV,SesslerDI,etal.Predistentionoftheepiduralspacebeforecatheter
labels;presencevs.absenceofsimilaritybetween2drugnames(2consecu- insertionreducestheincidenceofintravascularepiduralcatheterinsertionAnesthAnalg
tivesyllablesincommon);intra-colourvs.inter-coloursimilarity-wererandomly 2007;105:460–464.
allocatedto76distincttasks.ssE,Esel,OchkandFchkwereidentifiedusingdi-
rectandvideotapeobservation.Theimpactofthesefactorsonthefrequency
ofEsel,OchkandFchkwasanalysedinlogisticregression.Colourcodingdom- ESAAP1-3
inanceoverb&wwasassessedusingaprobabilisticriskassessmentmodel.
Coughtest,abdominalsurgeryandthecombinationofboth
TheprobabilityofssEwascomputedfromtheprobabilitiesofEsel,Ochk and aspredictivefactorsofpostoperativepulmonary
Fchk(PssE=PEselx(POchk+(1-POchk)xPFchk))whichwereobtainedbyboostrap complicationsandmortality
samplingofcorrespondingbinomialdistributions.Threescenarios(i.e.:b&w–
nosimilarityvs.colour–nosimilarity;b&w–similarityvs.colour–inter-colour A.Rojo,R.Armand-Ugón,Z.Briones,J.Vallès,L.Gallart
similarity;b&w–similarityvs.colour–intra-coloursimilarity)wereanalysedby Anesthesiology,HospitaldelMar-Esperança(IMAS).IMIM.UAB,Barcelona,
meansof10,000Monte-Carlosimulations. Catalonia,Spain
ResultsandDiscussion:ColourcodingdecreasesthefrequencyofEsel(8.8% Background and Goal of Study: Postoperative pulmonary complications
vs.17.4%;OR:2.2),increasestheoccurrenceofOchk(3.8%vs.0.6%;OR:6.6), (PPC)areassociated with substantial morbidity and mortality (1).Abdominal
andhasnoimpactonFchk.ThefrequencyofssEisreduced(0.2%vs.1.3%; surgery and positive cough test (CT) are relevant risk factors of PPC (1,2).
OR:6.0).Colourlabelsstronglydominateb&wlabelswhenthereisnosimilar- Therelevanceofcoughtestcouldbegreaterinpatientsundergoingabdom-
ity(99.6%;95%CI:99.41-99.68%),orwhensimilarityispresentwithindistinct inalsurgery,andtheaimofthisstudywastoevaluatethishypothesis.
colourcodes(100%;95%CI:99.97-100%).Colourlabelsprovideonlyaslight MaterialsandMethods:Weanalyzeddatafromaprospectivemulticenterco-
advantage whensimilarity exits withinthe same colour code (60.7%;95 CI: hortstudy(ARISCAT)performedin59hospitals.Forthepresentpartialstudy
59.68-61.61%). cardiacandthoracicsurgerywereexcluded.Coughtestwasperformedbyhav-
Conclusion(s):Useofcolourlabelsshouldbyrecommended.However,anaes- ingthepatienttakeadeepinspirationandcoughonce,andapositivetestwas
thesiologistsshouldbeawarethatwhenusingcolourcoding,hazardsremainas defined as recurrent coughing after thefirstcough (2).PPCregistered were
soonasdrugnamesimilaritiesarepresentwithinthesamecolourcode.Insuch respiratory infection,athelectasis,pleuraleffusionandbronchospasm.Three-
circumstances,otherdifferentiationmeanssuchasTallmanletters(ATROpine) month mortality was assessed by telephone. Patients were distributed in 4
shouldbeaddedtolimitsyringeselectionerrors. groupsconsideringabdominalsurgery(yes/no)andcoughtest(+/-).Chi-square
wasandmultivariableanalyseswereused.Thecontrolgroupwasestablished
fromnonabdominalsurgeryandnegativeCT.Genderandagewerealsocon-
ESAAP1-2 sidered.
ResultsandDiscussion:Table1showstheriskofPPC(2378patients).CT+
Doesthelateralrecumbenthead-downpositiondecreasethe
representsanincreasedriskofPPC,greatlyincreasedinpatientsundergoing
numberofepiduralvenouspuncturesduringcatheter
abdominalsurgery.
insertion?
M.Chanimov,M.Friedland,M.Cohen,M.Bahar,Z.Haitov Table1.RiskfactorsofPPC
DepartmentofAnesthesiology,AssafHarofehMedicalCenter,Affiliatedtothe
RiskFactors OR(95%CI)
SacklerFacultyofMedicine,TelAvivUniversity,Zerifin,Israel
Abdominalsurgeryno,CT-
BackgroundandGoalofStudy:Aninadvertentandunrecognizedepidural
Abdominalsurgeryno,CT+ 3.6(1.8–7.4)
veincannulationisapotentialcomplicationofepiduralanesthesia.Weevalu-
Abdominalsurgeryyes,CT- 9.6(5.3–17.4)
atedtheeffectofbodypostureduringepiduralcatheterinsertionontheriskof Abdominalsurgeryyes,CT+ 15.8(7.1–35.2)
bloodvesselpuncture. Gender 1.04(1.03–1.06)
MaterialsandMethods:Thestudysampleconsistedof900obstetricpatients Age 2.2(1.3–3.7)
withabodymassindex(BMI)lessthan35,450patientswithaBMIof35–40
PPC=Postoperativepulmonarycomplications;CT=coughtest;OR=Oddsratio.
whowereundergoingepiduralanalgesia,and347morbidclassIIIpatients.Pa-
tientswererandomizedtohaveepiduralcatheterizationinoneofthefollowing Table2showspostoperativemortalityrisk(2431patients).Asimilarpatternof
postures:sitting,lateralrecumbenthorizontalandlateralrecumbentheaddown riskwhenabdominalsurgeryandcoughtestareassociatedcanbeobserved.
position.Bloodvesselpuncturewasevidencedbybloodaspiration.
ResultsandDiscussion:OurresultsshowedthatasBMIincreased,theinci- Table1.RiskfactorsofMortality
denceofinadvertentepiduralveincannulationalsoincreased,butinthelateral
RiskFactors OR(95%CI)
recumbenthead-downpositionitsignificantlydecreased.
Abdominalsurgeryno,CT-
PrevalenceofSecondaryOutcomes Abdominalsurgeryno,CT+ 1.7(0.8–3.7)
Abdominalsurgeryyes,CT- 2.2(1.1–4.5)
Sitting Lateralrecumbent Lateralrecumbent p-value Abdominalsurgeryyes,CT+ 6.1(2.4–15.1)
position horizontalposition head-downposition Gender 1.1(1.06–1.11)
SampleSize 300 300 300 Age 3(1.5–5.8)
BodyMassIndex <35 <35 <35 PPC=Postoperativepulmonarycomplications;CT=coughtest;OR=Oddsratio.
BloodinCatheter 32(10.7%) 18(6.0%) 6(2.0%) 0.001
BloodinNeedle 6(2.0%) 4(1.3%) 1(0.3%) NS Ageandgenderalsoareindependentandrelevantfactorswhichhavetobe
>1Attempt 4.1% 3.8% 4.0% considered.
SampleSize 150 150 150 Conclusion(s):Positivecoughtest,abdominal surgeryandmainlythecom-
BodyMassIndex >35≤40 >35≤40 >35≤40 binationofbothvariablesarerelevantriskfactorsofpostoperativepulmonary
BloodinCatheter 20(12.0%) 11(7.3%) 3(2.0%) 0.001 complicationsandmortality,mainlyinagedandmalepatients.
BloodinNeedle 5(3.3%) 3(2.0%) 1(0.6%) NS Acknowledgements:GrantedfromMaratódeTV3041610(2003).
>1Attempt 16.6% 15.5% 16.0% References:
SampleSize 115 112 120 1 ArozullahAMetal.AnnSurg2000;232:242–53.
BodyMassIndex 43.2±4.5 42.9±5.3 44.6±4.9 2 McAlisterFAetal.AmJRespirCritCareMed2005;171:514–7.
BloodinCatheter 21(18.3%) 14(11.6%) 5(4.8%) 0.001
BloodinNeedle 7(6.8%) 5(5.35%) 4(3.3%) NS
>1Attempt 20.1% 22.0% 20.4% ESAAP1-4
NS=nonsignificant.
Noiseinpressuresupportimprovestheperformanceof
pressuresupportventilation
Conclusion(s):Thelateralrecumbenthead-downpositionforepiduralanalge-
siaforlaborattermsignificantlyreducestheriskofbloodvesselpuncture(1-3). M.GamadeAbreu,P.Spieth,P.Pelosi,A.Carvalho,T.Koch
References: ClinicofAnesthesiology,UniversityClinicCarlGustavCarus,Dresden,
1 BaharM,ChanimovM,CohenML,etal.Lateralrecumbenthead-downpostureforepidu- Germany
ralcatheterinsertionreducesintravascularinjection.CanJAnaesth2001;48:48–53.
2 BaharM,ChanimovM,CohenML,etal.Thelateralrecumbenthead-downpositionde- BackgroundandGoalofStudy:Biologicalsystemsmaybenefitfromnoise.
creasestheincidenceofepiduralvenouspunctureduringcatheterinsertioninobesepar- Inthepresentstudy,weaimedatdescribingandevaluatingtheeffectsofthe
turients.CanJAanesth2004;51:577–580. newnoisypressuresupportventilation(noisyPSV)onlungphysiologicalparam-
4 BestAbstracts–Runner-upSession2
etersinexperimentallunginjury.WehypothesizedthattheperformanceofPSV inMCFwhilepatientsreceivingplacebolost38%(p=0.016)duringsurgery,
canbeimprovedbyextrinsicnoise. witha30%differencebetweengroups(p=0.04).Despitesimilarprothrombin
MaterialsandMethods:Twelvepigsweighing25.0to36.5kgwereanes- converison,patientsintheF.XIIIvs.theplacebogrouphadsignificantlyreduced
thetized,hadthetracheaintubatedandlungsventilatedwithamechanicalven- fibrinogenconsumption(-28%,p=0.01).Also,bloodlosswassignificantlyre-
tilator(volume-controlled mode). Acutelunginjury wasthen inducedby sur- duced(-29%,p=0.041).Threepatientsexperiencedadverseevents,which
factantdepletion.Biphasicintermittentairwaypressure/airwaypressurerelease seemednotrelatedtoF.XIIIsubstitution.Thetrialwasstoppedearlyaftera
ventilation(BIPAP/APRV)wasinitiatedandanesthesiadepthwasdecreasedto plannedinterimanalysiswiththeprimaryendpointreached.
allowspontaneousbreathing.Afterthat,eachanimalwasventilatedwithfour Conclusion(s):Theseresultsconfirmourhypothesisthatpatientsathighrisk
differentmodesofassistedmechanicalventilation(1houreach,Latinsquares forintraoperativebloodlossbenefitfromearlyF.XIIIapplication.
sequence):1)PSV;2)PSVcombinedwithintermittentsighs(PSV+Sighs);3) Disclosure:W.Kortehasreceivedresearchsupportandspeakerfeesfrom
BIPAP/APRV+spontaneousbreathing;4)noisyPSVwithrandomvariationof CSLBehring.
pressuresupport(normaldistribution,coefficientofvariationof30%).Themean
levelofpressuresupportwassetidenticalinallPSVforms.Lungaerationwas
assessedbycomputedtomography andthedistributionofpulmonary blood
ESAAP1-6
flowwithintravenouslyadministeredcoloredmicrospheres.
Results andDiscussion: WefoundthatnoisyPSV:increasedtidalvolume Foreigncellsandsubstancesdragintothesubarachnoid
variabilitycomparedtoPSVandPSV+Sighs(19%vs.5%and7%,respectively, spaceduringspinalanesthesiainhumans:Incidencerelated
p<0.05)independentlyfromtheinspiratoryeffort;improvedoxygenationand toneedletypeandapproach
reducedvenousadmixture,butdidnotaffecttheamountofnon-aeratedlung F.Rocha,E.Ferreira,P.Amorim,J.Barbot
tissueascomparedtootherassistedventilationmodes;reducedmeanairway
Anestesia,HospitaldaPrelada,Porto,Portugal,Portugal
pressureatcomparableminuteventilation;redistributedpulmonarybloodflow
towardsnon-dependentlungregionssimilartootherPSVforms,whereasBI- BackgroundandGoalofStudy:Tissuecoringoccursinspinalanesthesiaas
PAP/APRV+spontaneousbreathingdidnot;reducedtheinspiratoryeffortand theneedledragsforeigncellswhengoingfromtheskintothesubarachnoid
cardiacoutputincomparisonwithBIPAP/APRV+spontaneousbreathing. space1.Tissuecoringbyepithelialcellshasbeenassociatedtothedevelop-
Conclusion(s):Inthesurfactantdepletionmodelofacutelunginjury,thenew mentofintraspinaltumors2.Westudiedthepresenceofepithelialcellsinthe
noisyPSVincreasedthevariabilityoftherespiratorypatternandimprovedoxy- CSFwhenperformingspinalanesthesia,factorsrelatedtoitandifrejectingthe
genationbyaredistributionofperfusiontowardstheventilatednon-dependent firstdropofCSFreducedthepresenceofepithelialcells.Thepresenceoftal-
lungregionswithsimultaneouslowermeanairwaypressure,comparableminute cumandothercellswasalsoevaluated.
ventilationandnoincreaseintheinspiratoryeffortorcardiacoutput. MaterialsandMethods:Prospectivestudyinpatientswithspinalanesthesia
Disclosure:Drs.GamadeAbreu,SpiethandKochweregrantedapatenton fororthopedicsurgery,randomizedto27Gor29GQuinckeneedlesandme-
noisyPSV.Dr.GamadeAbreureceivedaresearchgrantfromESAtoperform dianorparamedianapproach.ThefirstCSFdrop(alsothesecondin50cases)
thisstudy. wascollectedonamicroscopeslideandlefttodryintheopenair,stainedwith
References: hemacolorsolutionandanalyzedwithamicroscopebyananatomopathologist
1 GamadeAbreuetal.,Noisypressuresupportventilation:Apilotstudyonanewassisted whohadnopriorknowledgeoftheoriginofthesamples.Presenceofepithelial
ventilationmodeinexperimentallunginjury.CritCareMed,inpress. cellsandothercellsorsubstanceswasanalyzed.Dataaremean=SD.Statistics
usedt-testandChi-square;significanceforP<0,05).
ResultsandDiscussion:Therewere110patientsstudied.Spinalswere55
ESAAP1-5
witheachneedle,halfofeachbymedianandhalfbyparamedianapproach.
F.XIIIsubstitutioninpatientsathighriskforintraoperative Weobservedepithelialcellswithnucleusin5cases:4wereparamedianwith
bleedingsignificantlyreduceslossofclotfirmness, 27G and 1 paramedian with 29G. Type ofneedle was not related to tissue
consumptionoffibrinogenandbloodloss coring(P=0.2),buttheparamedianapproachwas(P<0.05).Scamouscellsap-
W.Korte,K.Gabi,V.Filipin,A.Gähler,T.Schnider pearedin65%,meningealcellsin45%andredbloodcellsin41%.In4ofthe
5caseswhereepithelialcellswerepresentwealsoanalyzedtheseconddrop
Institutef.Clin.Chemistry&HaematologyandDept.ofAnaesthesiology,
anddidnotfindepithelialcells.In75caseswedetectedthepresenceoftalcum
Kantonsspital,St.Gallen,Switzerland
powder;duetothis,weconducted10casesusingtalcumfreegloves(samples
BackgroundandGoalofStudy:Excessiveintraoperativebleedingisassoci- weredriedinaclosedbox)andnotracesoftalcumwerefound.
atedwithsignificantmorbidityandmortality.Weandothershaveshownthatfib- Conclusion(s):Inourhands,epithelialcellswerepresentinthefirstdropof
rinmonomer(FM)allowspreoperativeriskstratificationforintraoperativeblood CSFin5%ofcasesofspinalanesthesia.Thissuggeststhattissuecoringmay
loss duetoanimbalance between availableF.XIIIandprothrombin conver- havethatincidence,whichisofconcernduetopossiblerelationwithintraspinal
sion.WehypothesizedthatF.XIIIimprovesmaximumclotfirmness(MCF)and tumors.RejectingthefirstdropofCSFandusingthemedianapproachmight
reducesbloodlossinhighriskpatients. reducetheincidenceoftissuecoring,althoughthisremainstobeproven.Also,
MaterialsandMethods:Wetestedourhypothesisinaprospective,random- astalcumpresenceintheCSFwasreducedto0from75%whenpowdered
ized,doubleblind,placebocontrolledtrialinelectiveabdominalcancersurgery. gloves wereabandoned, itseemsadvisabletousetalcum-freegloveswhen
PatientswererandomizedtoreceiveF.XIII(30U/kg)orplaceboinadditionto doingspinalanesthesia.Morestudiesinthisfieldarejustified.
controlledstandardtherapy. References:
ResultsandDiscussion:Twentytwopatientswereevaluableforaplannedin- 1 RegAnesthPainMed2000;25(2):163–9.
terimanalysis.PatientsreceivingF.XIIIshowedanonsignificant8%decrease 2 Spine2004;1;29(1):15–8.
Best Abstracts– Runner-up Session 2
ESAAP2-1 MaterialsandMethods:MaleadultWistarratswereused.Focalcerebralis-
ImplicationofmitochondrialKATP-dependentchannel chemiawasperformedduring1hourfollowedby24hofreperfusion(I/R).Pre-
(mitoK )insevoflurane-inducedpreandpostconditioningin conditioningconsistedof15minexposuretosevofluraneat1MAC(2.6%)72h
ATP
thebrain beforeischemia(SPRE).Postconditioningwasobtainedbyexposuretosevoflu-
raneimmediatelyattheonsetofreperfusion(SPOST)oraftert+5min(delayed
S.Adamczyk,M.Simérabet,E.Robin,B.Vallet,G.Lebuffe
SPOST).ImplicationofmitoKATPchannelwasassessedbyintraperitonealinjec-
DepartmentofAnesthesiologyandIntensiveCare,UniversityHospitalofLille, tionoftheselectiveblocker5-hydroxydecanoate(5HD)oritsselectiveopener
Lille,France diazoxide(DZX).Infarctwasassessedbyhistomorphometricquantificationafter
BackgroundandGoalofStudy:Sevofluranehasshownexperimentaland 24hofreperfusion.Volumesaremeans±SEM.ANOVAwithLSDposthoctest
clinical benefits onmyocardium againstischemia-reperfusion. Wetested the forstatisticalanalysis;significantforp=0.05(*)or0.01(**)vsI/R.
neuroprotectiveeffectsofsevofluraneduringlatepreconditioningorpostcondi- Results and Discussion: Preconditioning and immediate postconditioning
tioninginaninvivomodeloffocalcerebralischemiaintherat.Implicationof withsevofluranesignificantlyreducedtotalcerebralinfarctby35%and45%.
mitoKATPwasalsoevaluated. Cortexandstriatumbothbenefitedoftheprotection.